drugset / Trial / NCT03776851

Erythropoietin in Hemolytic Uremic Syndrome

NCT03776851

Phase 4 Completed 24 enrolled Hospital General de Niños Pedro de Elizalde
RandomizedParallel-groupOpen-labelSupportive care

Summary

This study will evaluate the impact of early administration of erythropoietin in the number of red blood cell transfusions in children with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome (STEC-HUS).

Timeline

Start
2019-01-01
Primary completion
2020-12-30
Completion
2020-12-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic 50 iu/kg Subcutaneous